{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:59:14Z","timestamp":1795089554313,"version":"4.10.2"},"reference-count":85,"publisher":"Bentham Science Publishers Ltd.","issue":"15","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Botulinum toxin type A (BoNT-A) is widely employed for cosmetic purposes\nand in the treatment of certain diseases such as strabismus, hemifacial spasm and focal\ndystonia among others. BoNT-A effect mainly acts at the muscular level by inhibiting the release\nof acetylcholine at presynaptic levels consequently blocking the action potential in the neuromuscular\njunction. Despite the great progress in approval and pharmaceutical usage, improvement in\ndisplacing BoNT-A to other pathologies has remained very limited. Patients under diagnosis of\nseveral types of cancer experience pain in a myriad of ways; it can be experienced as hyperalgesia\nor allodynia, and the severity of the pain depends, to some degree, on the place where the tumor is\nlocated. Pain relief in patients diagnosed with cancer is not always optimal, and as the disease progresses,\ntransition to more aggressive drugs, like opioids is sometimes unavoidable. In recent years\nBoNT-A employment in cancer has been explored, as well as an antinociceptive drug; experiments\nin neuropathic, inflammatory and acute pain have been carried out in animal models and humans.\nAlthough its mechanism has not been fully known, evidence has shown that BoNT-A inhibits the\nsecretion of pain mediators (substance P, Glutamate, and calcitonin gene related protein) from the\nnerve endings and dorsal root ganglion, impacting directly on the nociceptive transmission through\nthe anterolateral and trigeminothalamic systems.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>The study aimed to collect available literature regarding molecular, physiological and neurobiological\nevidence of BoNT-A in cancer patients suffering from acute, neuropathic and inflammatory\npain in order to identify possible mechanisms of action in which the BoNT-A could impact\npositively in pain treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>BoNT-A could be an important neo-adjuvant and coadjuvant in the treatment of several\ntypes of cancer, to diminish pro-tumor activity and secondary pain.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200806105024","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T06:17:38Z","timestamp":1596867458000},"page":"2996-3009","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Mechanisms of Action of Botulinum Toxin Type A in Nociceptive and Neuropathic Pathways in Cancer Pain"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-0814","authenticated-orcid":true,"given":"Samuel","family":"Reyes-Long","sequence":"first","affiliation":[{"name":"Escuela Superior de Medicina, Instituto Politecnico Nacional, Ciudad de Mexico,Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4599-1253","authenticated-orcid":true,"given":"Alfonso","family":"Alfaro-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Division de Neurociencias, Instituto Nacional de Rehabilitacion, Secretaria de Salud, Ciudad de Mexico,Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-8535","authenticated-orcid":true,"given":"Jose Luis","family":"Cortes-Altamirano","sequence":"additional","affiliation":[{"name":"Division de Neurociencias, Instituto Nacional de Rehabilitacion, Secretaria de Salud, Ciudad de Mexico,Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-6362","authenticated-orcid":true,"given":"Eleazar","family":"Lara-Padilla","sequence":"additional","affiliation":[{"name":"Escuela Superior de Medicina, Instituto Politecnico Nacional, Ciudad de Mexico,Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-3585","authenticated-orcid":true,"given":"Elizabeth","family":"Herrera-Maria","sequence":"additional","affiliation":[{"name":"Universidad del Valle de Ecatepec, Estado de Mexico,Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-1231","authenticated-orcid":true,"given":"Pablo","family":"Romero-Morelos","sequence":"additional","affiliation":[{"name":"Universidad del Valle de Ecatepec, Estado de Mexico,Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Salcedo","sequence":"additional","affiliation":[{"name":"Laboratorio de Oncologia Genomica, Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, CMN-SXXI, IMSS, Ciudad de Mexico,Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Bandala","sequence":"additional","affiliation":[{"name":"Escuela Superior de Medicina, Instituto Politecnico Nacional, Ciudad de Mexico,Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1097\/00002508-200211001-00003","volume":"18","author":"Arezzo J.C.","year":"2002","unstructured":"Arezzo J.C.; Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 2002,18(6 Suppl.),S125-S132","journal-title":"Clin J Pain"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/toxins7072454","volume":"7","author":"Intiso D.","year":"2015","unstructured":"Intiso D.; Basciani M.; Santamato A.; Intiso M.; Di Rienzo F.; Botulinum toxin type A for the treatment of neuropathic pain in neuro-rehabilitation. Toxins (Basel) 2015,7(7),2454-2480","journal-title":"Toxins (Basel)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.3390\/toxins7083127","volume":"7","author":"Oh H.M.","year":"2015","unstructured":"Oh H.M.; Chung M.E.; Botulinum toxin for neuropathic pain: a review of the literature. Toxins (Basel) 2015,7(8),3127-3154","journal-title":"Toxins (Basel)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11916-016-0545-0","volume":"20","author":"Patil S.","year":"2016","unstructured":"Patil S.; Willett O.; Thompkins T.; Hermann R.; Ramanathan S.; Cornett E.M.; Fox C.J.; Kaye A.D.; Botulinum toxin: pharmacology and therapeutic roles in pain states. Curr Pain Headache Rep 2016,20(3),15","journal-title":"Curr Pain Headache Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.tox.2013.02.006","volume":"306","author":"Wheeler A.","year":"2013","unstructured":"Wheeler A.; Smith H.S.; Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 2013,306,124-146","journal-title":"Toxicology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"Aoki K.R.","year":"2005","unstructured":"Aoki K.R.; Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005,26(5),785-793","journal-title":"Neurotoxicology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1053\/apmr.2003.50121","volume":"84","author":"Lang A.M.","year":"2003","unstructured":"Lang A.M.; Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 2003,84(3 Suppl. 1),S69-S73","journal-title":"Arch Phys Med Rehabil"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neuroscience.2017.07.011","volume":"359","author":"Cobianchi S.","year":"2017","unstructured":"Cobianchi S.; Jaramillo J.; Luvisetto S.; Pavone F.; Navarro X.; Botulinum neurotoxin A promotes functional recovery after peripheral nerve injury by increasing regeneration of myelinated fibers. Neuroscience 2017,359,82-91","journal-title":"Neuroscience"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","volume":"107","author":"Cui M.","year":"2004","unstructured":"Cui M.; Khanijou S.; Rubino J.; Aoki K.R.; Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004,107(1-2),125-133","journal-title":"Pain"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.neuroscience.2017.06.040","volume":"358","author":"Matak I.","year":"2017","unstructured":"Matak I.; T\u00e9kus V.; B\u00f6lcskei K.; Lackovi\u0107 Z.; Helyes Z.; Involvement of substance P in the antinociceptive effect of botulinum toxin type A: evidence from knockout mice. Neuroscience 2017,358,137-145","journal-title":"Neuroscience"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.parkreldis.2011.06.013","volume":"17","author":"Aoki K.R.","year":"2011","unstructured":"Aoki K.R.; Francis J.; Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord 2011,17(Suppl. 1),S28-S33","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/mds.870020402","volume":"2","author":"Brin M.F.","year":"1987","unstructured":"Brin M.F.; Fahn S.; Moskowitz C.; Friedman A.; Shale H.M.; Greene P.E.; Blitzer A.; List T.; Lange D.; Lovelace R.E.; McMahon D.; Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987,2(4),237-254","journal-title":"Mov Disord"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","volume":"2","author":"Tsui J.K.C.","year":"1986","unstructured":"Tsui J.K.C.; Eisen A.; Stoessl A.J.; Calne S.; Calne D.B.; Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986,2(8501),245-247","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bbi.2013.01.088","volume":"32","author":"Vacca V.","year":"2013","unstructured":"Vacca V.; Marinelli S.; Luvisetto S.; Pavone F.; Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and \u03bc opioid receptor expression in neuropathic mice. Brain Behav Immun 2013,32,40-50","journal-title":"Brain Behav Immun"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.aat.2013.06.011","volume":"51","author":"Yen C-T.","year":"2013","unstructured":"Yen C-T.; Lu P-L.; Thalamus and Pain. Acta Anaesthesiol Taiwan 2013,51(2),73-80","journal-title":"Acta Anaesthesiol Taiwan"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.nlm.2013.06.008","volume":"105","author":"Rahn E.J.","year":"2013","unstructured":"Rahn E.J.; Guzman-Karlsson M.C.; David Sweatt J.; Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory. Neurobiol Learn Mem 2013,105,133-150","journal-title":"Neurobiol Learn Mem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pneurobio.2010.10.005","volume":"93","author":"Legrain V.","year":"2011","unstructured":"Legrain V.; Iannetti G.D.; Plaghki L.; Mouraux A.; The pain matrix reloaded: a salience detection system for the body. Prog Neurobiol 2011,93(1),111-124","journal-title":"Prog Neurobiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1124\/mi.10.3.7","volume":"10","author":"Schmidt B.L.","year":"2010","unstructured":"Schmidt B.L.; Hamamoto D.T.; Simone D.A.; Wilcox G.L.; Mechanism of cancer pain. Mol Interv 2010,10(3),164-178","journal-title":"Mol Interv"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"381434","DOI":"10.1100\/2012\/381434","volume":"2012","author":"Rosso M.","year":"2012","unstructured":"Rosso M.; Mu\u00f1oz M.; Berger M.; The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. ScientificWorldJournal 2012,2012,381434","journal-title":"ScientificWorldJournal"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00702-014-1182-6","volume":"121","author":"Stepulak A.","year":"2014","unstructured":"Stepulak A.; Rola R.; Polberg K.; Ikonomidou C.; Glutamate and its receptors in cancer. J Neural Transm (Vienna) 2014,121(8),933-944","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12022-019-9572-9","volume":"30","author":"Hodgson A.","year":"2019","unstructured":"Hodgson A.; Pakbaz S.; Tayyari F.; Young J.E.M.; Mete O.; Diagnostic pitfall: parathyroid carcinoma expands the spectrum of calcitonin and calcitonin gene-related peptide expressing neuroendocrine neoplasms. Endocr Pathol 2019,30(2),168-172","journal-title":"Endocr Pathol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/1073858414525828","volume":"20","author":"Schmidt B.L.","year":"2014","unstructured":"Schmidt B.L.; The neurobiology of cancer pain. Neuroscientist 2014,20(5),546-562","journal-title":"Neuroscientist"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tips.2018.11.003","volume":"40","author":"Majima M.","year":"2019","unstructured":"Majima M.; Ito Y.; Hosono K.; Amano H.; CGRP\/CGRP receptor antibodies: potential adverse effects due to blockade of neovascularization? Trends Pharmacol Sci 2019,40(1),11-21","journal-title":"Trends Pharmacol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/BCTT.S121610","volume":"8","author":"Weber L.V.","year":"2016","unstructured":"Weber L.V.; Al-Refae K.; W\u00f6lk G.; Bonatz G.; Altm\u00fcller J.; Becker C.; Gisselmann G.; Hatt H.; Expression and functionality of TRPV1 in breast cancer cells. Breast Cancer (Dove Med Press) 2016,8(8),243-252","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00774-017-0842-7","volume":"36","author":"Wakabayashi H.","year":"2018","unstructured":"Wakabayashi H.; Wakisaka S.; Hiraga T.; Hata K.; Nishimura R.; Tominaga M.; Yoneda T.; Decreased sensory nerve excitation and bone pain associated with mouse Lewis lung cancer in TRPV1-deficient mice. J Bone Miner Metab 2018,36(3),274-285","journal-title":"J Bone Miner Metab"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1080\/01616412.2019.1639317","volume":"41","author":"Zhang S.","year":"2019","unstructured":"Zhang S.; Zhao J.; Meng Q.; AAV-mediated siRNA against TRPV1 reduces nociception in a rat model of bone cancer pain. Neurol Res 2019,41(11),972-979","journal-title":"Neurol Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3517207","DOI":"10.1155\/2017\/3517207","volume":"2017","author":"Maqboul A.","year":"2017","unstructured":"Maqboul A.; Elsadek B.; A novel model of cancer-induced peripheral neuropathy and the role of TRPA1 in pain transduction. Pain Res Manag 2017,2017,3517207","journal-title":"Pain Res Manag"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/bs.mie.2019.07.043","volume":"629","author":"Di Virgilio F.","year":"2019","unstructured":"Di Virgilio F.; Jiang L-H.; Roger S.; Falzoni S.; Sarti A.C.; Vultaggio-Poma V.; Chiozzi P.; Adinolfi E.; Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells. Methods Enzymol 2019,629,115-150","journal-title":"Methods Enzymol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3892\/ijo.2019.4753","volume":"54","author":"Zhi X.","year":"2019","unstructured":"Zhi X.; Li B.; Li Z.; Zhang J.; Yu J.; Zhang L.; Xu Z.; Adrenergic modulation of AMPK dependent autophagy by chronic stress enhances cell proliferation and survival in gastric cancer. Int J Oncol 2019,54(5),1625-1638","journal-title":"Int J Oncol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/path.1002","volume":"196","author":"Jakobsen A-M.","year":"2002","unstructured":"Jakobsen A-M.; Ahlman H.; W\u00e4ngberg B.; K\u00f6lby L.; Bengtsson M.; Nilsson O.; Expression of synaptic vesicle protein 2 (SV2) in neuroendocrine tumours of the gastrointestinal tract and pancreas. J Pathol 2002,196(1),44-50","journal-title":"J Pathol"},{"key":"ref=31","first-page":"8411","volume":"8","author":"Bandala C.","year":"2015","unstructured":"Bandala C.; Cort\u00e9s-Algara A.L.; Mej\u00eda-Barradas C.M.; Ilizaliturri-Flores I.; Dominguez-Rubio R.; Baz\u00e1n-M\u00e9ndez C.I.; Floriano-S\u00e1nchez E.; Luna-Arias J.P.; Anaya-Ruiz M.; Lara-Padilla E.; Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. Int J Clin Exp Pathol 2015,8(7),8411-8418","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/pros.20958","volume":"69","author":"Karsenty G.","year":"2009","unstructured":"Karsenty G.; Rocha J.; Chevalier S.; Scarlata E.; Andrieu C.; Zouanat F.Z.; Rocchi P.; Giusiano S.; Elzayat E.A.; Corcos J.; Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate 2009,69(11),1143-1150","journal-title":"Prostate"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5301\/RU.2012.9254","volume":"79","author":"Proietti S.","year":"2012","unstructured":"Proietti S.; Nardicchi V.; Porena M.; Giannantoni A.; [Botulinum toxin type-A toxin activity on prostate cancer\ncell lines]. Urologia 2012,79(2),135-141","journal-title":"Urologia"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.7314\/APJCP.2012.13.10.5063","volume":"13","author":"Bandala C.","year":"2012","unstructured":"Bandala C.; Miliar-Garc\u00eda A.; Mej\u00eda-Barradas C.M.; Anaya-Ruiz M.; Luna-Arias J.P.; Baz\u00e1n-M\u00e9ndez C.I.; G\u00f3mez-L\u00f3pez M.; Ju\u00e1rez-M\u00e9ndez S.; Lara-Padilla E.; Synaptic vesicle protein 2 (SV2) isoforms. Asian Pac J Cancer Prev 2012,13(10),5063-5067","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.7314\/apjcp.2013.14.2.891","volume":"14","author":"Bandala C.","year":"2013","unstructured":"Bandala C.; Perez-santos J.L.M.; Lara-padilla E.; Delgado-Lopez G.; Anaya-Ruiz M.; Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pac J Cancer Prev 2013,14(2),891-894","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/pros.23454","volume":"78","author":"Coarfa C.","year":"2018","unstructured":"Coarfa C.; Florentin D.; Putluri N.; Ding Y.; Au J.; He D.; Ragheb A.; Frolov A.; Michailidis G.; Lee M.; Kadmon D.; Miles B.; Smith C.; Ittmann M.; Rowley D.; Sreekumar A.; Creighton C.J.; Ayala G.; Influence of the neural microenvironment on prostate cancer. Prostate 2018,78(2),128-139","journal-title":"Prostate"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/toxins8050126","volume":"8","author":"Hsu Y.C.","year":"2016","unstructured":"Hsu Y.C.; Wang H.J.; Chuang Y.C.; Intraprostatic botulinum neurotoxin type A injection for benign prostatic hyperplasia-a spotlight in reality. Toxins (Basel) 2016,8(5),2-9","journal-title":"Toxins (Basel)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0041-0101(99)00153-1","volume":"38","author":"Welch M.J.","year":"2000","unstructured":"Welch M.J.; Purkiss J.R.; Foster K.A.; Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000,38(2),245-258","journal-title":"Toxicon"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"21338","DOI":"10.1016\/S0021-9258(19)36614-1","volume":"267","author":"McMahon H.T.","year":"1992","unstructured":"McMahon H.T.; Foran P.; Dolly J.O.; Verhage M.; Wiegant V.M.; Nicholls D.G.; Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem 1992,267(30),21338-21343","journal-title":"J Biol Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/ana.24122","volume":"75","author":"Paterson K.","year":"2014","unstructured":"Paterson K.; Lolignier S.; Wood J.N.; McMahon S.B.; Bennett D.L.H.; Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction. Ann Neurol 2014,75(4),591-596","journal-title":"Ann Neurol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/toxins10060224","volume":"10","author":"Park J.","year":"2018","unstructured":"Park J.; Chung M.E.; Botulinum toxin for central neuropathic pain. Toxins (Basel) 2018,10(6),224","journal-title":"Toxins (Basel)"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/toxins9090260","volume":"9","author":"Park J.","year":"2017","unstructured":"Park J.; Park H.J.; Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel) 2017,9(9),260","journal-title":"Toxins (Basel)"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wcs.1201","volume":"4","author":"Melzack R.","year":"2013","unstructured":"Melzack R.; Katz. J Pain Wiley Interdiscip Rev Cogn Sci 2013,4(1),1-15","journal-title":"J Pain Wiley Interdiscip Rev Cogn Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.euroneuro.2011.05.005","volume":"22","author":"Nickel F.T.","year":"2012","unstructured":"Nickel F.T.; Seifert F.; Lanz S.; Maih\u00f6fner C.; Mechanisms of neuropathic pain. Eur Neuropsychopharmacol 2012,22(2),81-91","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2006.12.004","volume":"145","author":"Luvisetto S.","year":"2007","unstructured":"Luvisetto S.; Marinelli S.; Cobianchi S.; Pavone F.; Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007,145(1),1-4","journal-title":"Neuroscience"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1523\/JNEUROSCI.0375-08.2008","volume":"28","author":"Antonucci F.","year":"2008","unstructured":"Antonucci F.; Rossi C.; Gianfranceschi L.; Rossetto O.; Caleo M.; Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008,28(14),3689-3696","journal-title":"J Neurosci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejphar.2009.06.047","volume":"617","author":"Favre-Guilmard C.","year":"2009","unstructured":"Favre-Guilmard C.; Auguet M.; Chabrier P.E.; Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol 2009,617(1-3),48-53","journal-title":"Eur J Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/j.1526-4637.2011.01182.x","volume":"12","author":"Xiao L.","year":"2011","unstructured":"Xiao L.; Cheng J.; Dai J.; Zhang D.; Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over-expression in sensory neurons induced by ventral root transection in rats. Pain Med 2011,12(9),1385-1394","journal-title":"Pain Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1054\/jpai.2002.27142","volume":"3","author":"Borodic G.E.","year":"2002","unstructured":"Borodic G.E.; Acquadro M.A.; The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002,3(1),21-27","journal-title":"J Pain"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00002508-200503000-00010","volume":"21","author":"Allam N.","year":"2005","unstructured":"Allam N.; Brasil-Neto J.P.; Brown G.; Tomaz C.; Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain 2005,21(2),182-184","journal-title":"Clin J Pain"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1212\/01.wnl.0000180940.98815.74","volume":"65","author":"Piovesan E.J.","year":"2005","unstructured":"Piovesan E.J.; Teive H.G.; Kowaks P.A.; Della Coletta M.V.; Werneck L.C.; Silberstein S.D.; An open study of botulinum-a toxin treatment of trigeminal neuralgia. Neurology 2005,65(8),1306-1308","journal-title":"Neurology"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.wnf.0000172497.24770.b0","volume":"28","author":"T\u00fcrk U.","year":"2005","unstructured":"T\u00fcrk U.; Ilhan S.; Alp R.; Sur H.; Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005,28(4),161-162","journal-title":"Clin Neuropharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1590\/s0004-282x2008000400012","volume":"66","author":"Z\u00fa\u00f1iga C.","year":"2008","unstructured":"Z\u00fa\u00f1iga C.; D\u00edaz S.; Piedimonte F.; Micheli F.; Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr 2008,66(3A),500-503","journal-title":"Arq Neuropsiquiatr"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.tripleo.2009.03.021","volume":"109","author":"Ngeow W.C.","year":"2010","unstructured":"Ngeow W.C.; Nair R.; Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010,109(3),e47-e50","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1526-4637.2010.00801.x","volume":"11","author":"Yoon S.H.","year":"2010","unstructured":"Yoon S.H.; Merrill R.L.; Choi J.H.; Kim S.T.; Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury. Pain Med 2010,11(4),630-632","journal-title":"Pain Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tripleo.2010.04.043","volume":"111","author":"Bohluli B.","year":"2011","unstructured":"Bohluli B.; Motamedi M.H.K.; Bagheri S.C.; Bayat M.; Lassemi E.; Navi F.; Moharamnejad N.; Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011,111(1),47-50","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/0333102412441721","volume":"32","author":"Wu C.J.","year":"2012","unstructured":"Wu C.J.; Lian Y.J.; Zheng Y.K.; Zhang H.F.; Chen Y.; Xie N.C.; Wang L.J.; Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012,32(6),443-450","journal-title":"Cephalalgia"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/01.sla.0000141156.56314.1f","volume":"240","author":"Layeeque R.","year":"2004","unstructured":"Layeeque R.; Hochberg J.; Siegel E.; Kunkel K.; Kepple J.; Henry-Tillman R.S.; Dunlap M.; Seibert J.; Klimberg V.S.; Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg 2004,240(4),608-613","journal-title":"Ann Surg"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1533-2500.2007.00150.x","volume":"7","author":"Kapural L.","year":"2007","unstructured":"Kapural L.; Stillman M.; Kapural M.; McIntyre P.; Guirgius M.; Mekhail N.; Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case series. Pain Pract 2007,7(4),337-340","journal-title":"Pain Pract"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ana.21427","volume":"64","author":"Ranoux D.","year":"2008","unstructured":"Ranoux D.; Attal N.; Morain F.; Bouhassira D.; Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008,64(3),274-283","journal-title":"Ann Neurol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/01.wnl.0000345968.05959.cf","volume":"72","author":"Yuan R.Y.","year":"2009","unstructured":"Yuan R.Y.; Sheu J.J.; Yu J.M.; Chen W.T.; Tseng I.J.; Chang H.H.; Hu C.J.; Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009,72(17),1473-1478","journal-title":"Neurology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2340\/00015555-0609","volume":"89","author":"Sotiriou E.","year":"2009","unstructured":"Sotiriou E.; Apalla Z.; Panagiotidou D.; Ioannidis D.; Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm Venereol 2009,89(2),214-215","journal-title":"Acta Derm Venereol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1111\/j.1526-4637.2010.01003.x","volume":"11","author":"Xiao L.","year":"2010","unstructured":"Xiao L.; Mackey S.; Hui H.; Xong D.; Zhang Q.; Zhang D.; Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med 2010,11(12),1827-1833","journal-title":"Pain Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/AJP.0b013e31827a72d2","volume":"29","author":"Apalla Z.","year":"2013","unstructured":"Apalla Z.; Sotiriou E.; Lallas A.; Lazaridou E.; Ioannides D.; Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain 2013,29(10),857-864","journal-title":"Clin J Pain"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","volume":"128","author":"Burns P.B.","year":"2011","unstructured":"Burns P.B.; Rohrich R.J.; Chung K.C.; The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg 2011,128(1),305-310","journal-title":"Plast Reconstr Surg"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/toxins8010018","volume":"8","author":"Moon Y.E.","year":"2016","unstructured":"Moon Y.E.; Choi J.H.; Park H.J.; Park J.H.; Kim J.H.; Ultrasound-guided nerve block with botulinum toxin type A for intractable neuropathic pain. Toxins (Basel) 2016,8(1),18","journal-title":"Toxins (Basel)"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/ana.24605","volume":"79","author":"Han Z.A.","year":"2016","unstructured":"Han Z.A.; Song D.H.; Oh H.M.; Chung M.E.; Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol 2016,79(4),569-578","journal-title":"Ann Neurol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S1474-4422(16)00017-X","volume":"15","author":"Attal N.","year":"2016","unstructured":"Attal N.; de Andrade D.C.; Adam F.; Ranoux D.; Teixeira M.J.; Galhardoni R.; Raicher I.; \u00dc\u00e7eyler N.; Sommer C.; Bouhassira D.; Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2016,15(6),555-565","journal-title":"Lancet Neurol"},{"key":"ref=69","first-page":"608","volume":"46","author":"Ding X.D.","year":"2017","unstructured":"Ding X.D.; Zhong J.; Liu Y.P.; Chen H.X.; Botulinum as a toxin for treating post-herpetic neuralgia. Iran J Public Health 2017,46(5),608-611","journal-title":"Iran J Public Health"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"7365148","DOI":"10.1155\/2018\/7365148","volume":"2018","author":"Liu J.","year":"2018","unstructured":"Liu J.; Xu Y.Y.; Zhang Q.L.; Luo W.F.; Efficacy and safety of botulinum toxin type A in treating patients of advanced age with idiopathic trigeminal neuralgia. Pain Res Manag 2018,2018,7365148","journal-title":"Pain Res Manag"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrc747","volume":"2","author":"Mantyh P.W.","year":"2002","unstructured":"Mantyh P.W.; Clohisy D.R.; Koltzenburg M.; Hunt S.P.; Molecular mechanisms of cancer pain. Nat Rev Cancer 2002,2(3),201-209","journal-title":"Nat Rev Cancer"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","volume":"51","author":"van den Beuken-van Everdingen M.H.J.","year":"2016","unstructured":"van den Beuken-van Everdingen M.H.J.; Hochstenbach L.M.J.; Joosten E.A.J.; Tjan-Heijnen V.C.G.; Janssen D.J.A.; Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 2016,51(6),1070-1090.e9","journal-title":"J Pain Symptom Manage"},{"key":"ref=73","author":"Tseng T.-H.","year":"2008","unstructured":"Tseng T.-H.; Lin C.-C.; [Cancer pain]. \nHu Li Za Zhi.,\n55(2), 16-21.2008"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clon.2011.03.003","volume":"23","author":"Middlemiss T.","year":"2011","unstructured":"Middlemiss T.; Laird B.J.A.; Fallon M.T.; Mechanisms of cancer-induced bone pain. Clin Oncol (R Coll Radiol) 2011,23(6),387-392","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neulet.2013.08.003","volume":"557","author":"Lozano-Ondoua A.N.","year":"2013","unstructured":"Lozano-Ondoua A.N.; Symons-Liguori A.M.; Vanderah T.W.; Cancer-induced bone pain: mechanisms and models. Neurosci Lett 2013,557(Pt A),52-59","journal-title":"Neurosci Lett"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3959(03)00241-0","volume":"104","author":"Jung B.F.","year":"2003","unstructured":"Jung B.F.; Ahrendt G.M.; Oaklander A.L.; Dworkin R.H.; Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain 2003,104(1-2),1-13","journal-title":"Pain"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1526-4637.2012.01437.x","volume":"13","author":"Mittal S.","year":"2012","unstructured":"Mittal S.; Machado D.G.; Jabbari B.; OnabotulinumtoxinA for treatment of focal cancer pain after surgery and\/or radiation. Pain Med 2012,13(8),1029-1033","journal-title":"Pain Med"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.apmr.2017.12.032","volume":"99","author":"De Groef A.","year":"2018","unstructured":"De Groef A.; Devoogdt N.; Van Kampen M.; Nevelsteen I.; Smeets A.; Neven P.; Geraerts I.; Dams L.; Van der Gucht E.; Debeer P.; Effectiveness of botulinum toxin a for persistent upper limb pain after breast cancer treatment: a double-blinded randomized controlled trial. Arch Phys Med Rehabil 2018,99(7),1342-1351","journal-title":"Arch Phys Med Rehabil"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1533-2500.2012.00569.x","volume":"13","author":"Fabregat G.","year":"2013","unstructured":"Fabregat G.; Asensio-Samper J.M.; Palmisani S.; Villanueva-P\u00e9rez V.L.; De Andr\u00e9s J.; Subcutaneous botulinum toxin for chronic post-thoracotomy pain. Pain Pract 2013,13(3),231-234","journal-title":"Pain Pract"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1200\/jco.2003.99.030","volume":"21","author":"De Micheli C.","year":"2003","unstructured":"De Micheli C.; Fornengo P.; Bosio A.; Epifani G.; Pascale C.; Severe radiation-induced proctitis treated with botulinum anatoxin type A. J Clin Oncol 2003,21(13),2627","journal-title":"J Clin Oncol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1001\/jamadermatol.2015.1793","volume":"151","author":"Naik H.B.","year":"2015","unstructured":"Naik H.B.; Steinberg S.M.; Middelton L.A.; Hewitt S.M.; Zuo R.C.; Linehan W.M.; Kong H.H.; Cowen E.W.; Efficacy of intralesional botulinum toxin A for treatment of painful cutaneous leiomyomas: a randomized clinical trial. JAMA Dermatol 2015,151(10),1096-1102","journal-title":"JAMA Dermatol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/asj\/sjv040","volume":"35","author":"Gabriel A.","year":"2015","unstructured":"Gabriel A.; Champaneria M.C.; Maxwell G.P.; The efficacy of botulinum toxin A in post-mastectomy breast reconstruction: a pilot study. Aesthet Surg J 2015,35(4),402-409","journal-title":"Aesthet Surg J"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/toxins8010022","volume":"8","author":"Rostami R.","year":"2016","unstructured":"Rostami R.; Mittal S.O.; Radmand R.; Jabbari B.; Incobotulinum toxin-A improves post-surgical and post-radiation pain in cancer patients. Toxins (Basel) 2016,8(1),22","journal-title":"Toxins (Basel)"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/bja\/aen100","volume":"101","author":"Delaney A.","year":"2008","unstructured":"Delaney A.; Fleetwood-Walker S.M.; Colvin L.A.; Fallon M.; Translational medicine: cancer pain mechanisms and management. Br J Anaesth 2008,101(1),87-94","journal-title":"Br J Anaesth"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"10886","DOI":"10.1523\/jneurosci.19-24-10886.1999","volume":"19","author":"Schwei M.J.","year":"1999","unstructured":"Schwei M.J.; Honore P.; Rogers S.D.; Salak-Johnson J.L.; Finke M.P.; Ramnaraine M.L.; Clohisy D.R.; Mantyh P.W.; Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999,19(24),10886-10897","journal-title":"J Neurosci"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200806105024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184588\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200806105024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T07:51:42Z","timestamp":1655797902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184588\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":85,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200806105024","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}